Loading market information…
TAI · 6919.TW · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Caliway Biopharmaceuticals Co. L’s quoted price sits in the lower half of its reported 52-week range, 64.57% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Caliway Biopharmaceuticals Co. L’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -NT$0.25. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Caliway Biopharmaceuticals Co. L’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| NT$12.00M0.0% vs estimate |
| Q1 2025 | May 5, 2025 | -NT$0.11+22.45% vs estimate | NT$9.35M+133.69% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -NT$0.09+31.46% vs estimate | NT$23.00M+91.67% vs estimate |
|---|
| Q2 2024 | Aug 9, 2024 | -NT$0.12+12.16% vs estimate | NT$8.00M-33.33% vs estimate |
|---|
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
